Drug Landscape ›
Interferon-Gamma ›
Regulatory · United States
Marketing authorisation
FDA
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
Window: 20 April 2025 – 20 April 2026
Total reports: 395
Most-reported reactions
Drug Ineffective — 58 reports (14.68%) Off Label Use — 58 reports (14.68%) Neutropenia — 54 reports (13.67%) Pyrexia — 54 reports (13.67%) Nausea — 35 reports (8.86%) Respiratory Failure — 31 reports (7.85%) Pneumonia — 28 reports (7.09%) Anaemia — 26 reports (6.58%) Hypotension — 26 reports (6.58%) Dehydration — 25 reports (6.33%)
Source database →
Interferon-Gamma in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Frequently asked questions
Is Interferon-Gamma approved in United States?
Yes. FDA has authorised it.
Who is the marketing authorisation holder for Interferon-Gamma in United States?
SPP Pharmaclon Ltd. is the originator. The local marketing authorisation holder may differ — check the official source linked above.